FDA-approved1,2,3Evidence: Large human trialsMetabolic and weight

Lixisenatide1

Also called Soliqua 100/33, Adlyxin1,2,3

Key takeaway

Lixisenatide is a GLP-1 receptor agonist, a peptide that acts like a gut hormone involved in blood-sugar control. Drugs@FDA lists it as the active ingredient of Sanofi’s Adlyxin, first approved on July 27, 2016.2,3 It is FDA-approved, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes, both on its own as Adlyxin and combined with insulin glargine as Soliqua 100/33.1,2 In ELIXA, a randomized trial of 6,068 adults with type 2 diabetes after a recent heart attack or unstable angina, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.2

Lixisenatide at a glance

What it isA GLP-1 receptor agonist. The Adlyxin label states that it increases insulin release when blood sugar is high, decreases glucagon release and slows stomach emptying.2
FDA statusFDA-approved. Drugs@FDA lists Adlyxin with an original approval date of July 27, 2016; lixisenatide is also a component of Soliqua 100/33. Neither cited label has a boxed warning.1,2,3
Human evidenceLarge randomized trials described in the labels, including the ELIXA cardiovascular safety trial and two trials of the insulin glargine combination.1,2
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is lixisenatide?

Lixisenatide is a lab-made peptide that the Adlyxin label describes as a GLP-1 receptor agonist.2

Drugs@FDA lists it as the active ingredient of Adlyxin, from Sanofi. The Soliqua 100/33 label describes a combination of insulin glargine and lixisenatide.1,3

How does lixisenatide work?

The Adlyxin label states that lixisenatide increases insulin release when blood sugar is high, decreases glucagon release and slows stomach emptying.2

The label reports that its effect on blood sugar after meals was most notable after the first meal of the day and weaker after later meals.2

What do human studies show?

In ELIXA, described in the Adlyxin label, 6,068 adults with type 2 diabetes and a recent acute coronary syndrome were randomized to lixisenatide or placebo and followed for a median of about 26 months.2

The hazard ratio for the main outcome, a composite of cardiovascular death, heart attack, stroke or hospitalization for unstable angina, was 1.02, and the label states that the upper limit of its confidence interval, 1.17, excluded the prespecified risk margin of 1.3. The trial was designed to rule out increased risk, not to show a reduction.2

The Soliqua 100/33 label describes two 30-week randomized trials in 1,170 and 736 adults with type 2 diabetes, in which the combination produced statistically significant improvements in HbA1c, a measure of long-term blood sugar, compared with the active comparators.1

What the evidence base contains

  • Large randomized human trial ELIXA: a randomized, double-blind, placebo-controlled trial in 6,068 adults with type 2 diabetes after a recent acute coronary syndrome, designed to rule out an increase in cardiovascular risk.2
  • Large randomized human trial Two 30-week randomized, active-controlled trials of Soliqua 100/33 in 1,170 and 736 adults with type 2 diabetes (NCT05058147 and NCT02058160).1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is lixisenatide FDA-approved?

Yes. Drugs@FDA lists Adlyxin, application BLA208471, with an original approval date of July 27, 2016.3

The Adlyxin prescribing information cited here (revised November 2024) states that it is indicated, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes, that it should not be used in type 1 diabetes, and that it is not recommended in people with gastroparesis.2

The Soliqua 100/33 label cited here (DailyMed SPL version 25, published March 20, 2026) states that the combination of insulin glargine and lixisenatide is indicated, with diet and exercise, to improve blood-sugar control in adults with type 2 diabetes.1

Neither label has a boxed warning. The Adlyxin label states that it is contraindicated in people with severe allergic reactions to it, and its warnings cover anaphylaxis, acute pancreatitis, low blood sugar with insulin or insulin secretagogues, acute kidney injury, antibodies, gallbladder disease and aspiration during anesthesia or deep sedation.2

Timeline

  1. FDA approves Adlyxin, according to Drugs@FDA.3
  2. FDA-hosted Adlyxin prescribing information is revised to the version cited on this page.2
  3. DailyMed publishes the Soliqua 100/33 label version cited on this page.1

What is still unknown?

Whether lixisenatide reduces cardiovascular events: ELIXA was designed to rule out increased risk, not to show benefit.2

Its effects in people with a history of pancreatitis or with gastroparesis, in whom the Adlyxin label says it has not been studied.2

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Lixisenatide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Lixisenatide are the records PeptideScanner has selected and published, not every registration or paper about Lixisenatide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Adlyxin and in Soliqua 100/33. Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.↗↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 15, 2026 · Review version 1.

Review source snapshots checked September 15, 2026 · Integrity checked September 15, 2026.

Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.↗↗

What the reviewed sources report

ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.↗↗

What remains unresolved?

  • How do the monotherapy and fixed-combination regulatory records differ?↗↗
  • What do the broader diabetes program and subsequent Parkinson trials establish?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

ADLYXIN, revised November 2024 · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

This single-ingredient label covers glycemic control alongside diet and exercise in adults with type 2 diabetes. It is separate from the insulin glargine/lixisenatide combination label cited by the profile, and does not establish current commercial availability. Label: 1 ↗

Which safety limits matter?

The label contraindicates severe hypersensitivity and addresses anaphylaxis, pancreatitis, hypoglycemia with insulin or insulin secretagogues, acute kidney injury, immunogenicity, gallbladder disease and aspiration during anesthesia or deep sedation. It does not recommend use in gastroparesis. Label: 4, 5, 6 ↗

Label edition and source pins

FDA-hosted U.S. prescribing information. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

ADLYXIN, revised November 2024: U.S. prescribing information

Label PDF SHA-256: 62efbf5418ef53b5e665d679c1184fa7bc006960fb487a68aa04bf1e2a04d597.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Lixisenatide?

Manually reviewed September 15, 2026 · version 1

Browse all Human Evidence Reviews · Open preserved synthesis version 1 →

Two selected trials address cardiovascular outcomes in type 2 diabetes and exploratory motor outcomes in early Parkinson disease. These are lixisenatide trials, not evidence for the insulin-glargine combination as an interchangeable intervention.12

Bottom line from this bounded source set

ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.12

Reviewed study record

ELIXA: cardiovascular outcomes

Design

Randomized placebo-controlled trial added lixisenatide or placebo to usual care.1

Population

6,068 people with type 2 diabetes and a recent acute coronary event were followed for a median of 25 months.1

Outcomes reported

The primary cardiovascular composite occurred in 13.4% versus 13.2%; hazard ratio 1.02 (95% CI 0.89–1.17). Noninferiority was met, superiority was not. Serious adverse events were not more frequent with lixisenatide.1

Limitations

The result is a cardiovascular safety comparison in a high-risk population, not evidence of cardiovascular benefit or the entire glycemic-efficacy program.1

Reviewed study record

LIXIPARK: exploratory Parkinson trial

Design

Randomized, double-blind, placebo-controlled phase 2 trial with 12 months of treatment and a two-month washout.2

Population

156 people with early Parkinson disease were randomized while receiving stable symptomatic therapy.2

Outcomes reported

The between-group difference in motor-score change at 12 months was 3.08 points favoring lixisenatide. Nausea occurred in 46% and vomiting in 13% of active-group participants.2

Limitations

The primary assessment was in the on-medication state. A small phase 2 study cannot establish disease modification, long-term benefit or safety; larger trials are required.2

Reviewed source set

  1. PubMed · 26630143Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. ↗PubMed PMID 26630143 · EFetch XML reviewed 2026-09-15 · payload SHA-256 115be31c54d4952d6d390218d4c3015c727c520d819e34874e529579c32c2176
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa1509225. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 38598572Trial of Lixisenatide in Early Parkinson's Disease. ↗PubMed PMID 38598572 · EFetch XML reviewed 2026-09-15 · payload SHA-256 1c89844dd46e395e8dfdf02f0b578335e189cb034eb66edd1a1a3f0fb7c169f7
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1056/nejmoa2312323. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

The initial assessment focused on glucose control

EMA’s November 2012 review found HbA1c improvements when lixisenatide was added to specified background therapies. Placebo-adjusted changes and changes from baseline differed, and results varied between trial populations. EMA PDF pp. 77, 79 ↗

More findings, study links and document coverage

A comparison did not robustly establish equivalence

EMA judged noninferiority to exenatide on glycemic and weight outcomes not robustly demonstrated. A favorable overall regulatory decision did not mean every comparative endpoint was established. EMA PDF pp. 79 ↗

Safety interpretation needs the background regimen

The review identifies gastrointestinal symptoms, injection-site and allergic reactions, with hypoglycemia principally alongside insulin or sulfonylureas. Evidence in people over 75 and those with substantial kidney impairment was limited. EMA PDF pp. 77, 78, 79 ↗

Keep the historical review separate from later status

ELIXA was still ongoing in this assessment. The downloaded PDF is now marked as a product no longer authorized, so its original favorable recommendation is not proof of current EU authorization or later cardiovascular benefit. EMA PDF pp. 1, 80 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 1 inventoried documents; 0 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

One selected official document from the retained EMA document inventory or an independently retrieved FDA application package. Other formulations, later variations, national records and the wider source inventory remain outside this reading. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

  • Lyxumia : EPAR - Public assessment report ↗

    Selected sections reviewed · ema-28007 · Document/feed date: 2026-02-05

    Application identity and document date were checked in the PDF, independently of the URL year or candidate feed association.

    Verified: Lyxumia · EMEA/H/C/002445 · Document dated 2012-11-28. Identity checked on PDF pp. 1.

    Selected identity, clinical-summary and benefit-risk sections only; this is not a full-document or all-indication appraisal.

    Retrieved 2026-09-19. Read PDF pages: 1, 77, 78, 79, 80 of 81. SHA-256: bb64000d8ce3d69605a1b93466e94e1f08615da94f32e7f6c684f8a1853e4922.

    Feed-listed application (not a verified association): EMEA/H/C/002445.

Remaining work

  • Review ELIXA results separately from the original glucose-control program.
  • Verify the withdrawal history and current jurisdiction-specific products without inferring a safety cause from the withdrawal watermark.

Open versioned document coverage and study pins →

European medicine records · 2 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

  • Suliqua ↗

    Authorised · EMEA/H/C/004243

    Active substance as listed: insulin glargine;lixisenatide. EMA record ↗

    Marketing authorisation: 2017-01-11. EMA metadata last updated 2026-09-08. EMA metadata ↗

  • Lyxumia ↗

    Withdrawn · EMEA/H/C/002445

    Active substance as listed: lixisenatide. EMA record ↗

    Authorisation withdrawal, expiry, revocation or lapse: 2025-12-18. EMA metadata last updated 2026-02-05. EMA metadata ↗

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.

731 retrieved · 2 included · 0 excluded · 729 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"lixisenatide"[Title/Abstract] OR "Adlyxin"[Title/Abstract] OR "Lyxumia"[Title/Abstract] OR "AVE0010"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.

Showing 25 of 731 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 38598572 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT03439943.
  2. PubMed 26630143 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT01147250.
  3. PubMed 42473266 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  4. PubMed 42697752 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  5. PubMed 42692277 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42687799 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 42556625 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 42401410 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 42387313 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 42698423 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 42609010 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 30000034 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 42666495 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 42584027 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 42296503 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 42259643 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 42186210 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 42025665 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 41792979 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 40145958 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 42536323 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 42490867 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 41994910 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 41444101 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 42452511 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LIXISENATIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:20.426246+00:00 · HTTP 200 · SHA-256 52975787c4c73c59eeda23a5adc9bd409cf0b7c1ecb610165e61aea10d76da2a.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA BLA208673 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: INSULIN GLARGINE, LIXISENATIDE.
  2. FDA BLA208471 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LIXISENATIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

2 retrieved · 2 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Lixisenatide", "Soliqua 100/33"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 2 of 2 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/004243 — include: EMA feed product Suliqua; reported status: Authorised. Exact indication and decision documents remain unappraised.
  2. EMA EMEA/H/C/002445 — include: EMA feed product Lyxumia; reported status: Withdrawn. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

25 retrieved · 16 included · 0 excluded · 9 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Lixisenatide", "Soliqua 100/33"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 25 of 25 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 20482 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Public assessment report
  2. EMA 30245 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - All Authorised presentations
  3. EMA 38350 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Medicine overview
  4. EMA 46983 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-PSUSA-00010577-201905 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  5. EMA 47100 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-4243-II-0011: EPAR - Assessment Report- Variation
  6. EMA 55983 — include: Document linked by EMA product number; content unappraised. Suliqua-H-C-PSUSA-00010577-202111 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  7. EMA 49818 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Risk-management-plan summary
  8. EMA 28007 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Public assessment report
  9. EMA 32330 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - All Authorised presentations
  10. EMA 39362 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  11. EMA 64723 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Procedural steps taken and scientific information after authorisation
  12. EMA 13355 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Summary for the public
  13. EMA 41911 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  14. EMA 21962 — include: Document linked by EMA product number; content unappraised. Lyxumia : EPAR - Product Information
  15. EMA 21301 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Product Information
  16. EMA 74418 — include: Document linked by EMA product number; content unappraised. Suliqua : EPAR - Procedural steps taken and scientific information after authorisation
  17. EMA 52578 — not screened: Title-name match awaiting identity and document review. P/0443/2020 : EMA decision of 1 December 2020 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M07)
  18. EMA 28652 — not screened: Title-name match awaiting identity and document review. P/18/2011: EMA decision of 24 January 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for lixisenatide (EMEA-000916-PIP01-10) in accordance with...
  19. EMA 43773 — not screened: Title-name match awaiting identity and document review. P/0380/2018: of 7 December 2018 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M06)
  20. EMA 15493 — not screened: Title-name match awaiting identity and document review. P/0076/2012: EMA decision of 25 April 2012 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA- 000916-PIP01-10-M02)
  21. EMA 24408 — not screened: Title-name match awaiting identity and document review. P/0035/2013: EMA decision of 27 February 2013 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide, (EMEA-000916-PIP01-10-M03)
  22. EMA 26848 — not screened: Title-name match awaiting identity and document review. P/225/2011: EMA decision of 27 September 2011 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (EMEA- 000916-PIP01-10-M01)
  23. EMA 29319 — not screened: Title-name match awaiting identity and document review. P/168/2010: European Medicines Agency decision of 3 September 2010 on the granting of a product specific waiver for lixisenatide / insulin glargine, (EMEA-000915-PIP01-10)
  24. EMA 41211 — not screened: Title-name match awaiting identity and document review. P/0037/2015: EMA decision of 6 March 2015 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia) (EMEA-000916-PIP01-10-M04)
  25. EMA 41987 — not screened: Title-name match awaiting identity and document review. P/0133/2016: EMA decision of 20 May 2016 on the acceptance of a modification of an agreed paediatric investigation plan for lixisenatide (Lyxumia), (EMEA-000916-PIP01-10-M05)

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Lixisenatide", "Soliqua 100/33"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    77 retrieved · 0 included · 0 excluded · 77 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Lixisenatide" OR "Soliqua 100/33" OR "Suliqua" OR "Lyxumia"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:37.727814+00:00 · HTTP 200 · SHA-256 bdda076efe1ebae2665d67b06921b3c4adcab9247da30f819e4c7697cae6e80d.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 77 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT01960179 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT02276196 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT02058160 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT03798054 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT03881995 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT00931372 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT00763451 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT04196231 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT07173712 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT03819790 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT02767596 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT02501850 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT01572649 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT02713477 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT01147250 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT07274644 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT00715624 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT01146678 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT00763815 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT02168491 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT03798080 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT06716424 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT05136287 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT00707031 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT00866658 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Lixisenatide?

    FDA-approved as Adlyxin and in Soliqua 100/33. Large randomized trials described in the labels support these uses. In the ELIXA trial of 6,068 adults after a recent acute coronary syndrome, the results ruled out a prespecified increase in major cardiovascular risk compared with placebo.↗↗↗

    The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

    Evidence present

    What records are connected here?

    Evidence lanes
    3
    Source years
    12
    Drugs@FDA applications
    1

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Latest source-dated record

    What changed most recently at a cited source?

    Literature metadata · source date July 30, 2026

    PubMed record PMID 39604042↗Added to PeptideScanner August 10, 2026

    Coverage gaps

    What remains unknown or unsupported?

    PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Lixisenatide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    64Selected dated records
    66Connected citations
    12Populated source years2015–2026
    3/4Record lanes present

    Registered human studies

    Trial composition

    2 of 6 selected trial records include at least one phase value; 2 of 6 include a status value in the retained structured contract.

    25 public history versions connect to 5 of these trial records across 10 submitted years. Open the record-history collection →

    PhasesNot applicable 1Phase 4 1
    Status at observationCompleted 2

    A phase value is unavailable here for 4 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 4 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    14 of 34 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 11Research Support, Non-U.S. Gov't 5Comment 3Letter 3Clinical Trial, Phase II 1Clinical Trial, Phase III 1Comparative Study 1Network Meta-Analysis 1Randomized Controlled Trial 1Review 1Systematic Review 1

    Bibliography fields unavailable here for 20 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    1
    FDA Federal Register documents
    3
    DailyMed SPL versions
    20
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    64

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts
    Source records by collection · 64 dated records

    Research hub

    Explore the Lixisenatide evidence record

    Open all 64 records →
    64Dated records
    3Evidence types
    64Cited public sources
    12Source years

    Change ledger

    Recently changed for Lixisenatide

    Open all 67 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Profile status changed

    Lixisenatide profile

    We added a plain-language reader guide with cited answers drawn from the Adlyxin and Soliqua 100/33 labels, and added the Drugs@FDA approval record for Adlyxin.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile
    Record added

    ClinicalTrials.gov record NCT02745470

    PeptideScanner retained ClinicalTrials.gov record NCT02745470 at 2026-07-30T21:22:00.254Z. Its registry update date was 2017-11-29, and PeptideScanner's reviewed identity mapping was lixisenatide.

    PeptideScanner change date
    September 9, 2026
    Cited source date
    November 29, 2017
    Evidence lane
    Clinical trials

    Official-source collections

    Source records for Lixisenatide

    Open the full research atlas →
    PubMed34

    14 with attributed title, venue, publication-date, and type metadata.

    1. Poly(l-threonine-co-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.Biomacromolecules · 2024 07 01
    2. Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) compared with premix or addition of meal-time insulin to basal insulin in people with type 2 diabetes: A systematic review and Bayesi…Diabetes, obesity & metabolism · 2020 09 03
    3. Glycaemic target attainment in people with Type 2 diabetes treated with insulin glargine/lixisenatide fixed-ratio combination: a post hoc analysis of the LixiLan-O and LixiLan-L trials.Diabetic medicine : a journal of the British Diabetic Association · 2019 11 26
    Explore all selected literature →
    ClinicalTrials.gov6

    25 public history versions across these dated registry records; status labels apply only to each cited observation.

    1. NCT03439943Registry update November 28, 2025 · completed at observation
    2. NCT02049034Registry update December 16, 2024 · completed at observation
    3. NCT02640118Registry update May 7, 2020 · completed at observation
    Explore all selected trial records →Explore all public record history →
    DailyMed SPL history20

    Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

    1. SPL version 25Published 2026-03-20 · ZIP SHA-256 e0f67a6ccd0f…
    2. SPL version 23Published 2025-08-01 · ZIP SHA-256 a8b9de04de70…
    3. SPL version 22Published 2025-06-13 · ZIP SHA-256 9b3ef7156a69…
    4. SPL version 19Published 2024-11-14 · ZIP SHA-256 af0908969b3e…
    5. SPL version 18Published 2023-10-12 · ZIP SHA-256 8ae271652824…
    Explore all DailyMed label versions →

    Evidence types

    Coverage by source year

    Selected records span December 15, 2015 to July 30, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Organizations and trial records named in cited sources

    Organizations named in cited records

    • U.S. National Library of Medicine1
    • U.S. Food and Drug Administration2,3
    Dated updates connected to this profile · 64

    Updates connected to this profile

    Open the full cross-source timeline →
    1. Literature metadata

      PubMed record PMID 39604042↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39604042 at 2026-07-30T16:31:16.748Z. PubMed recorded a metadata revision date of 2026-07-30 and an Entrez history date of 2024-11-27. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    2. Literature metadata

      PubMed record PMID 38870730↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38870730 at 2026-08-10T18:13:32.367Z. PubMed recorded a metadata revision date of 2026-07-02 and an Entrez history date of 2024-06-13. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    3. Literature metadata

      PubMed record PMID 38685598↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38685598 at 2026-07-30T16:14:06.932Z. PubMed recorded a metadata revision date of 2026-06-18 and an Entrez history date of 2024-04-30. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    4. Literature metadata

      PubMed record PMID 38877681↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38877681 at 2026-07-30T16:20:38.897Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-06-15. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    5. Literature metadata

      PubMed record PMID 39407425↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39407425 at 2026-07-30T16:20:39.038Z. PubMed recorded a metadata revision date of 2026-05-31 and an Entrez history date of 2024-10-16. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    6. Literature metadata

      PubMed record PMID 22564709↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 22564709 at 2026-07-30T16:20:34.419Z. PubMed recorded a metadata revision date of 2026-05-18 and an Entrez history date of 2012-05-09. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    7. Literature metadata

      PubMed record PMID 39157869↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 39157869 at 2026-07-30T16:23:36.341Z. PubMed recorded a metadata revision date of 2026-03-23 and an Entrez history date of 2024-08-19. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    8. Regulatory

      Lixisenatide DailyMed SPL version 25↗

      DailyMed lists Structured Product Labeling version 25 for the reviewed Lixisenatide label family with a published date of 2026-03-20. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

    9. Literature metadata

      PubMed record PMID 41623754↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41623754 at 2026-07-30T16:25:14.225Z. PubMed recorded a metadata revision date of 2026-02-04 and an Entrez history date of 2026-02-02. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    10. Literature metadata

      PubMed record PMID 25012990↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 25012990 at 2026-07-30T16:30:52.644Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-12. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    11. Literature metadata

      PubMed record PMID 25055456↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 25055456 at 2026-07-30T16:30:52.649Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-07-25. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    12. Literature metadata

      PubMed record PMID 25115916↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 25115916 at 2026-07-30T16:30:52.653Z. PubMed recorded a metadata revision date of 2026-01-28 and an Entrez history date of 2014-08-14. PeptideScanner associated this retained record with the identity slug lixisenatide. These dates describe PubMed metadata history, not the article's original publication date.↗

    Citations

    Sources

    Coverage and sources →

    Numbered markers in the text point here. Each link opens the original public record.

    1. 1
      SOLIQUA 100/33 (insulin glargine and lixisenatide) injection · SPL version 25 · published 2026-03-20 ↗

      DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

    2. 2
      ADLYXIN, revised November 2024: U.S. prescribing information ↗

      U.S. Food and Drug Administration · Official source · Source checked September 15, 2026

    3. 3
      Drugs@FDA application BLA208471 · original submission status AP · 2016-07-27 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026